Trials / Not Yet Recruiting
Not Yet RecruitingNCT05452928
Aciclovir Versus Placebo for HSV-2 Meningitis
Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Jacob Bodilsen · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acyclovir 50 MG/ML | Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period. |
| DRUG | Placebo | Placebo either in IV formulation or as tablets identical to valacyclovir tablets. |
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2028-06-01
- Completion
- 2029-06-01
- First posted
- 2022-07-12
- Last updated
- 2025-10-01
Source: ClinicalTrials.gov record NCT05452928. Inclusion in this directory is not an endorsement.